Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03870854
Other study ID # CTO-PA #1723
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date August 13, 2019
Est. completion date September 30, 2025

Study information

Verified date November 2023
Source Queen's University
Contact Dmitry Uchitel
Phone 613-533-2148
Email dmitry.uchitel@kingstonhsc.ca
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Canadian multicentre prospective cohort study of 40 patients with ischaemic heart disease and therapy from an implantable cardioverter defibrillator (ICD).


Description:

Paced Electrogram Feature Analysis is employed to elucidate VT isthmus sites and target Type I sites for ablation to prevent recurrent VT/VF. The trial hypothesis is: catheter ablation employing PEFA will, in comparison to published data, reduce the composite outcome of death at any time, appropriate ICD shock, ventricular tachycardia storm or treated sustained ventricular tachycardia below the detection rate of the ICD or incessant VT for patients with prior myocardial infarction and sustained ventricular tachycardia or fibrillation.


Recruitment information / eligibility

Status Recruiting
Enrollment 40
Est. completion date September 30, 2025
Est. primary completion date August 30, 2024
Accepts healthy volunteers No
Gender All
Age group 19 Years and older
Eligibility Inclusion Criteria: - greater than 18 years of age - Ischaemic heart disease and prior myocardial infarction (using the international definition of MI: Q waves or imaging evidence of regional myocardial akinesis/thinning in the absence of a non-ischemic cause with documentation of prior ischaemic injury) - Eligible for catheter ablation as standard of care - Implantable Cardioverter Defibrillator Exclusion Criteria: - Unable or unwilling to provide consent - Both mechanical aortic and mitral valve - LV thrombus, - NYHA class IV heart failure symptoms - Contraindication to heparin - Survival limited to <1 year in estimation of attending care team, - Prior VT ablation Exclusion to standard of care VT catheter ablation procedure such as - Active ischaemia (acute thrombus diagnosed by coronary angiography, or dynamic ST segment changes demonstrated on ECG) or another reversible cause of VT (e.g. drug- induced arrhythmia), had recent acute coronary syndrome within 30 days thought to be due to acute coronary arterial thrombosis, or have CCS functional class IV angina. Note that biomarker level elevation alone after ventricular arrhythmias does not denote acute coronary syndrome or active ischemia. - Non-ischaemic cardiomyopathy because of reduced ablation success and PEFA has not been examined in the context of a non-ischaemic cardiomyopathy

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
PEFA VT ablation technique
Catheter ablation guided by PEFA technique

Locations

Country Name City State
Canada Kingston Health Sciences Centre Kingston Ontario
Canada London Health Sciences Centre London Ontario
Canada University of Ottawa Heart Institutation Ottawa Ontario

Sponsors (1)

Lead Sponsor Collaborator
Dr. Damian Redfearn

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary All-cause mortality a composite of death - any time post procedure myocardial infarction and sustained ventricular tachycardia or fibrillation. 3 years
Primary Appropriate ICD shock Time to first appropriate ICD shock - any time post procedure 3 years
Primary VT storm Time to 3 or more episodes of VT within 24 hours - any time post procedure 3 years
Primary Treated sustained VT below the detection rate of the ICD Time to any sustained VT below the detection rate of the ICD; e.g. by external cardioversion, pharmacologic conversion, or manual ICD therapy - any time post procedure 3 years
Primary Incessant VT Time to incessant VT defined as a sustained ventricular arrhythmia which does not terminate despite appropriate external cardioversion/defibrillation or ICD antitachycardia pacing or shocks, or terminates but reinitiates within =5 seconds - any time post procedure 3 years
Secondary Appropriate anti-tachycardia pacing (ATP) from ICD Appropriate anti-tachycardia pacing (ATP) from ICD - any time post procedure 3 years
Secondary Inducible for ventricular arrhythmia Number of inducible for ventricular arrhythmia following catheter ablation guided by PEFA protocol 3 years
Secondary Number of ventricular arrhythmia events This is a composite of appropriate ATP, appropriate shock, sustained VT not treated by ICD, external cardioversion, or pharmacologic cardioversion, and incessant VT - any time during or after the procedure 3 years
Secondary Escalation and De-escalation of antiarrhythmic medication Any increase or decrease in the dosage of antiarrhythmic medication either due to inefficacy or side effects will be assessed - any time post procedure 3 years